Search Results

• • 1,796 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Select Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports

  1

  Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports

  Authors:Kenneth Thomsen, Jon Diernaes, Trine Heide Ollegaard, Eva Spaun, and Christian VestergaardFrom:Case Reports in Dermatology (Vol. 10, Issue 2) Peer-Reviewed

  May-August 20181,610 words Article 1280LCheckpoint inhibitors are novel and promising treatment options for different types of cancer. Programmed cell death 1 (PD-1) inhibitors, such as pembrolizumab, have been shown to significantly raise the survival rates...
• Select nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial

  2

  nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial

  Authors:Cesare Gridelli, Tianlei Chen, Amy Ko, Mary E. O'Brien, Teng Jin Ong, Mark A. Socinski, et al.From:Drug Design, Development and Therapy (Vol. 10) Peer-Reviewed

  Annual 20183,770 words Article 1900LBackground: Limited data on elderly patients with squamous advanced non-small cell lung cancer (NSCLC) preclude optimal treatment. Here, we report the outcomes of a retrospective analysis of a subset of patients...
• Select Predictive biomarkers for checkpoints, first tests approved

  3

  Predictive biomarkers for checkpoints, first tests approved

  Author:Ken GarberFrom:Nature Biotechnology (Vol. 33, Issue 12) Peer-Reviewed

  Dec. 20151,413 words Article 1290LThe US Food and Drug Administration (FDA) on 2 October gave the go-ahead to the first pairing of a companion diagnostic with an immune-checkpoint inhibitor, for second-line treatment of metastatic non-small cell lung...
• Select Extremely Long Survival under Combined Immunotherapy in a Metastatic Functional Neuroendocrine Neoplasia Patient

  4

  Extremely Long Survival under Combined Immunotherapy in a Metastatic Functional Neuroendocrine Neoplasia Patient

  Authors:Daniel Schmidt and Bertram WiedenmannFrom:Neuroendocrinology (Vol. 106, Issue 4) Peer-Reviewed

  May 20182,736 words Article 1520LTreatment and prognosis of neuroendocrine neoplasia depends on tumor size, stage, grade, resectability, and extent of distant metastasis. In most cases a multimodality approach including surgical, locally invasive...
• Select Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report

  5

  Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report

  Authors:Raffaele Nettuno and Carmine MendittoFrom:Oncology (Vol. 94, Issue S1) Peer-Reviewed

  July 24, 20181,784 words Article 1560LEribulin, a non-taxane inhibitor of microtubule dynamics, is approved for the treatment of metastatic breast cancer patients after progression with anthracyclines and taxanes. Nevertheless, to our knowledge, information...
• Select Findings on Serum Globulins Described by Researchers at Harvard University School of Medicine (Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the ...)

  6

  Findings on Serum Globulins Described by Researchers at Harvard University School of Medicine (Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the ...)

  From:Obesity, Fitness & Wellness Week

  May 11, 2019412 words Report 1310L2019 MAY 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Proteins - Serum Globulins is the subject of a report. According to news reporting from Boston,...
• Select Findings from P.A. Janne and Co-Authors in the Area of Cytokine-Induced Killer Cells Reported (A High-throughput Immune-oncology Screen Identifies Egfr Inhibitors As Potent Enhancers of Antigen-specific Cytotoxic T-lymphocyte Tumor Cell Killing)

  7

  Findings from P.A. Janne and Co-Authors in the Area of Cytokine-Induced Killer Cells Reported (A High-throughput Immune-oncology Screen Identifies Egfr Inhibitors As Potent Enhancers of Antigen-specific Cytotoxic T-lymphocyte Tumor Cell Killing)

  From:Obesity, Fitness & Wellness Week

  June 22, 2019536 words Article 1450L2019 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Immunology - Cytokine-Induced Killer Cells is now available. According to news reporting originating...
• Select New Findings in the Area of Non-Small Cell Lung Cancer Reported from S. Bravaccini and Colleagues (What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?)

  8

  New Findings in the Area of Non-Small Cell Lung Cancer Reported from S. Bravaccini and Colleagues (What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?)

  From:Obesity, Fitness & Wellness Week

  June 8, 2019420 words Report 1350L2019 JUN 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Oncology - Non-Small Cell Lung Cancer are discussed in a new report. According to news reporting...
• Select Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma.

  9

  Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma.

  Authors:Nobuki Furubayashi, Takahito Negishi, Dai Takamatsu, Kosuke Ieiri, Tomohiro Inoue, Keiji Tsukino, et al.From:Oncology Letters (Vol. 19, Issue 4) Peer-Reviewed

  Apr. 20204,292 words Article 1510LCisplatin-based systemic chemotherapy is the gold-standard approach for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (UC). However, the optimal number of cycles is still unclear....
• Select BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

  10

  BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

  Authors:Bruno Bockorny, Valerya Semenisty, Teresa Macarulla, Erkut Borazanci, Brian M. Wolpin, Salomon M. Stemmer, et al.From:Nature Medicine (Vol. 26, Issue 6) Peer-Reviewed

  June 20209,048 words Report 1590LAuthor(s): Bruno Bockorny 1 2 , Valerya Semenisty 3 , Teresa Macarulla 4 , Erkut Borazanci 5 6 , Brian M. Wolpin 2 7 , Salomon M. Stemmer 8 9 , Talia Golan 9 10 , Ravit Geva 11 12 , Mitesh J. Borad 13 , Katrina S....
• Select Treatment timing well tolerated in bladder cancer

  11

  Treatment timing well tolerated in bladder cancer

  Author:Louise StoneFrom:Nature Reviews Urology (Vol. 16, Issue 4) Peer-Reviewed

  Apr. 2019130 words Author abstract, Bri... 1320LAuthor(s): Louise Stone 1 Author Affiliations: (1) Nature Reviews Urology, Pembrolizumab can be safely combined with either sequential or concomitant stereotactic body radiotherapy (SBRT) for treating...
• Select Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.

  12

  Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.

  Authors:Steven D. Criss, Lauren Palazzo, Tina R. Watson, Adelle M. Paquette, Keith Sigel, Juan Wisnivesky, et al.From:PLoS ONE (Vol. 15, Issue 1) Peer-Reviewed

  Jan. 29, 20205,204 words Article 1610LObjectives While previous cost-effectiveness studies on pembrolizumab in stage IV non-small cell lung cancer (NSCLC) have found these regimens to be cost-effective, their reliance on randomized controlled trial (RCT)...
• Select Pancreatic undifferentiated carcinoma with osteoclast-like giant cells curatively resected after pembrolizumab therapy for lung metastases: a case report

  13

  Pancreatic undifferentiated carcinoma with osteoclast-like giant cells curatively resected after pembrolizumab therapy for lung metastases: a case report

  Authors:Miku Obayashi, Yasushi Shibasaki, Toru Koakutsu, Yoshiro Hayashi, Tsuyoshi Shoji, Kazuhisa Hirayama, et al.From:BMC Gastroenterology (Vol. 20, Issue 1) Peer-Reviewed

  July 11, 20203,318 words Clinical report 1570LAuthor(s): Miku Obayashi1 , Yasushi Shibasaki1 , Toru Koakutsu1 , Yoshiro Hayashi 1 , Tsuyoshi Shoji1 , Kazuhisa Hirayama1 , Masanori Yamazaki1 , Yasuhiro Takayanagi2 , Hiroshi Shibata3 , Masato Nakamura4 and Hirotoshi...
• Select Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

  14

  Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy

  Authors:Matteo Pallocca, Davide Angeli, Fabio Palombo, Francesca Sperati, Michele Milella, Frauke Goeman, et al.From:Journal of Translational Medicine (Vol. 17, Issue 1) Peer-Reviewed

  Apr. 23, 20193,959 words Report 1450LBackground There are no accepted universal biomarkers capable to accurately predict response to immuno-checkpoint inhibitors (ICI). Although recent literature has been flooded with studies on ICI predictive...
• Select Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

  15

  Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

  Authors:Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, et al.From:Nature Medicine (Vol. 25, Issue 6) Peer-Reviewed

  June 20196,787 words Report 1590LBlocking programmed death 1 (PD-1) may enhance the durability of anti-tumor responses that are induced by the combined inhibition of BRAF and MEK.sup.1. Here we performed a randomized phase 2 trial...
• Select Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy

  16

  Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy

  Authors:Gregory S. Alexander, Joshua D. Palmer, Madalina Tuluc, Jianqing Lin, Adam P. Dicker, Voichita Bar-Ad, et al.From:Journal of Hematology & Oncology (Vol. 9, Issue 1) Peer-Reviewed

  Sept. 23, 20164,237 words Case study 1530LBackground Pembrolizumab is a monoclonal antibody that is designed against programmed cell death protein 1 (PD-1). Pembrolizumab and other immunocheckpoint-blocking monoclonal antibodies work by modulating a...
• Select FGFR-TKI resistance in cancer: current status and perspectives.

  17

  FGFR-TKI resistance in cancer: current status and perspectives.

  Authors:Sitong Yue, Yukun Li, Xiaojuan Chen, Juan Wang, Meixiang Li, Yongheng Chen, et al.From:Journal of Hematology & Oncology (Vol. 14, Issue 1) Peer-Reviewed

  Feb. 10, 20216,895 words Article 1450LFibroblast growth factor receptors (FGFRs) play key roles in promoting the proliferation, differentiation, and migration of cancer cell. Inactivation of FGFRs by tyrosine kinase inhibitors (TKI) has achieved great...
• Select Quadruple-negative breast cancer: novel implications for a new disease.

  18

  Quadruple-negative breast cancer: novel implications for a new disease.

  Authors:Shristi Bhattarai, Geetanjali Saini, Keerthi Gogineni, and Ritu AnejaFrom:Breast Cancer Research (Vol. 22, Issue 1) Peer-Reviewed

  Nov. 19, 20206,311 words Disease/Disorder ove... 1450LBased on the androgen receptor (AR) expression, triple-negative breast cancer (TNBC) can be subdivided into AR-positive TNBC and AR-negative TNBC, also known as quadruple-negative breast cancer (QNBC). QNBC...
• Select Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report.

  19

  Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report.

  Authors:Ah-Reum Jeong, Kimberly Forbes, Ryan K. Orosco, and Ezra E. W. CohenFrom:Journal of Otolaryngology - Head & Neck Surgery (Vol. 51, Issue 1) Peer-Reviewed

  Feb. 5, 20223,215 words Report 1340LBackground Germline CDKN2A mutations are a well-known cause of familial atypical multiple mole melanoma (OMIM #155601) and melanoma-pancreatic cancer syndrome (OMIM #606719). Increased risk of head and neck squamous...
• Select Effect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients.

  20

  Effect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients.

  Authors:Kazuaki Yasui, Ryota Kondou, Akira Iizuka, Haruo Miyata, Emiko Tanaka, Tadashi Ashizawa, et al.From:Journal of Radiation Research (Vol. 61, Issue 5) Peer-Reviewed

  Sept. 20204,587 words Article 1530LThe aim of the study was to investigate the effect of chemo-radiation on the genetic and immunological status of rectal cancer patients who were treated with preoperative chemoradiotherapy (CRT). The expression of immune...